Candel Therapeutics (CADL) Asset Utilization Ratio (2021 - 2022)
Candel Therapeutics' (CADL) quarterly Asset Utilization Ratio came in at 0.0 in Q4 2022, up 42.55% year-on-year from 0.0 in Q4 2021, and up 37.27% quarter-over-quarter from 0.0 in Q3 2022.
Candel Therapeutics (CADL) Asset Utilization Ratio (2021 - 2022) Analysis & Trends
Candel Therapeutics has disclosed Asset Utilization Ratio across 2 years of filings, most recently posting 0.0 for Q4 2022.
- Asset Utilization Ratio for Q4 2022 came in at 0.0, up 42.55% year-over-year; the trailing twelve-month figure through Dec 2022 was 0.0 (up 42.55% YoY), and the FY2022 annual result was 0.0, down 4.52% from the prior year.
- Asset Utilization Ratio came in at 0.0 for Q4 2022 at Candel Therapeutics, up from 0.0 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.0 in Q3 2021 to a low of 0.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 0.55 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.60 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 1,422.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Candel Therapeutics | 440.62 Mn | 440.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 0.00 |
| Sep 30, 2022 | 0.00 |
| Jun 30, 2022 | 0.00 |
| Mar 31, 2022 | 0.00 |
| Dec 31, 2021 | 0.00 |
| Sep 30, 2021 | 0.00 |